Researcher Spotlight: Antonio Ferreira, PHD BRIGHAM AND WOMEN’S HOSPITAL The tumor microenvironment, comprised of both tumor cells and healthy cells, may play a role in growth and proliferation of malignant cells. Dr. Ferreira’s LRF research, funded under the Foundation’s larger…
Researcher Spotlight: Clarissa Corinaldesi, PHD COLUMBIA UNIVERSITY Burkitt lymphoma (BL) is a rare but highly aggressive form of lymphoma that primarily affects children and young adults. While many patients are effectively cured with aggressive chemotherapy, a small subset of patients…
Researcher Spotlight: Ivan Cohen, PHD PERELMAN SCHOOL OF MEDICINE, UNIVERSITY OF PENNSYLVANIA Chimeric antigen receptor (CAR) T cell therapy is a form of immunotherapy that modifies a patient’s own immune cells to recognize and kill tumor cells. Anti-CD19 CAR T…
Researcher Spotlight: Tomohiro Aoki, MD, PHD BC CANCER Interactions between tumor cells and healthy cells leads to the formation of a tumor microenvironment that can affect response to treatment. These relationships are bidirectional: Pressure from healthy immune cells can lead…
Researcher Spotlight: BOYU HU, MD THE UNIVERSITY OF UTAH Some patients with chronic lymphocytic leukemia (CLL) respond poorly to treatment due to genetic changes that affect primary DNA damage repair (DDR) mechanisms targeted by currently approved agents. Instead, the CLL…
Researcher Spotlight: Lorenzo Falchi, MD MEMORIAL SLOAN KETTERING CANCER CENTER For the last two decades, follicular lymphoma (FL) has been treated with traditional chemotherapy. While effective, this treatment is not considered curative and can cause a host of short- and…
Researcher Spotlight: Zachary Epstein-Peterson, MD MEMORIAL SLOAN KETTERING CANCER CENTER Peripheral T-cell lymphomas are a rare and challenging group of malignancies to treat. Mutations in the isocitrate dehydrogenase 2 (IDH2) enzyme have been identified in a subgroup of patients with…
Researcher Spotlight: Juan Alderuccio, MD MILLER SCHOOL OF MEDICINE OF THE UNIVERSITY OF MIAMI Relapsed or refractory follicular lymphoma (FL) is considered an incurable lymphoma malignancy, with most patients needing lifelong treatment. Loncastuximab tesirine is an antibody-drug conjugate that targets…